Literature DB >> 12901033

Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution.

Geraldine M Ferron1, Sherry Ku, Madelyn Abell, Mary Unruh, John Getsy, Philip R Mayer, Jeffrey Paul.   

Abstract

The bioavailability of pantoprazole when administered as a suspension in sodium bicarbonate solution and as the oral tablet was studied. In an open-label, randomized, two-period crossover study, healthy fasting subjects received either one enteric-coated 40-mg pantoprazole tablet by mouth with 240 mL of water or 20 mL of a suspension prepared from one crushed pantoprazole tablet and 840 mg of sodium bicarbonate solution and administered via a nasogastric tube. Treatments were separated by a 48-hour washout period. Blood samples were collected at intervals up to 24 hours after drug administration for measurement of pantoprazole concentration by high-performance liquid chromatography (HPLC) and estimation of pharmacokinetic values. A separate study was conducted to determine pantoprazole's stability in the suspension for up to three months at 25, 5, and -20 degrees C; concentrations were measured by HPLC. Twelve subjects completed the study. The suspension yielded pantoprazole Cmax values similar to those of the tablet formulation, but the drug was 25% less bioavailable. There was no lag time for the suspension. The suspension was stable for up to two weeks at 5 degrees C and up to three months at -20 degrees C. A suspension of pantoprazole in sodium bicarbonate solution yielded a Cmax similar to that of the tablet formulation, and the drug was quickly absorbed. However, bio-availability was slightly lower with the suspension than with the tablet.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901033     DOI: 10.1093/ajhp/60.13.1324

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  7 in total

1.  Administration of proton pump inhibitors in patients requiring enteral nutrition.

Authors:  Terri M Wensel
Journal:  P T       Date:  2009-03

Review 2.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.

Authors:  Zeruesenay Desta; Anil Modak; Phuong D Nguyen; Suzanne M Lemler; Yasuhisa Kurogi; Lang Li; David A Flockhart
Journal:  J Pharmacol Exp Ther       Date:  2009-01-09       Impact factor: 4.030

4.  Comparative anti-ulcerogenic study of pantoprazole formulation with and without sodium bicarbonate buffer on pyloric ligated rat.

Authors:  Papiya Bigoniya; A Shukla; C S Singh; P Gotiya
Journal:  J Pharmacol Pharmacother       Date:  2011-07

Review 5.  Oral drug therapy in elderly with dysphagia: between a rock and a hard place!

Authors:  Serena Logrippo; Giovanna Ricci; Matteo Sestili; Marco Cespi; Letizia Ferrara; Giovanni F Palmieri; Roberta Ganzetti; Giulia Bonacucina; Paolo Blasi
Journal:  Clin Interv Aging       Date:  2017-01-31       Impact factor: 4.458

6.  Influence of Proton Pump Inhibitors and Histamine Receptor 2 Antagonists on Blastocystis ST3 and Selected Microorganisms of Intestinal Microbiota In Vitro.

Authors:  Małgorzata Lepczyńska; Ewa Dzika; WenChieh Chen; Chien-Yu Lu
Journal:  Clin Transl Gastroenterol       Date:  2021-04-09       Impact factor: 4.396

7.  Appropriateness of administration of nasogastric medication and preliminary intervention.

Authors:  Ling-Ling Zhu; Ling-Cheng Xu; Hui-Qin Wang; Jing-Fen Jin; Hua-Fen Wang; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2012-11-20       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.